Highlights beim Mammakarzinom

• Verwenden Sie folgende Direktlinks, um im Video zu navigieren:
• 04:19 - DESTINY-Breast
• 03:15 - TROPiCS-02
• 04:28 - MAINTAIN
• 05:46 - ASTER 70s
• 06:43 - ABCSG-18

Assoz.-Prof. Priv.-Doz. Dr. Rupert Bartsch präsentiert klinisch relevante Studienhighlights beim Mammakarzinom, wobei unter anderem Antikörper-Drug-Konjugate (ADCs) ihren Erfolgszug bei der metastasierten Erkrankung fortsetzen: In der DESTINY-Breast04-Studie zeigte das ADC Trastuzumab Deruxtecan bei vorbehandelten Patientinnen mit niedriger HER2-Expression (HR+ oder triple-negativ) eine deutliche Verlängerung des progressionsfreien sowie des Gesamtüberlebens verglichen mit einer Standardchemotherapie nach Wahl des Prüfarztes.

DESTINY-Breast: Modi S et al., Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. Abstract #LBA3

TROPiCS-02: Rugo HA et al., Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. Abstract #LBA1001

MAINTAIN: Kalinsky K et al., A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. Abstract #LBA1004

ASTER 70s: Brain E et al., Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial. Abstract #500

ABCSG-18: Gnant M et al., Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial. Abstract #507